ABSTRACT
Ultrasound-guided permanent prostate brachytherapy (PPB) alone or in conjunction with external beam radiotherapy (EBRT) for adenocarcinoma of the prostate is quickly growing in popularity as a treatment option for patients with early stage, localized cancers. As experience with this technique has grown over the last several years, reports in the literature have presented the urinary morbidity from several centers.1-3 The rectal morbidity associated with PPB has been less well investigated and documented.4,5 As patients are asked to participate in the treatment decisions for early stage, localized prostate cancer, the morbidity of each treatment method plays an important role in the selection process for each patient.
